Floatz logo

Therapeutic Asset Ratings

6,308 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Pd-L1 T-Hank
Triple-Negative Breast Carcinoma
ImmunityBio, Inc.P1/2CCC (48)
pds01adc
Human Papilloma Virus Infection
National Cancer Institute (NCI)P1/2CCC (48)
pds01adc
Head And Neck Cancer
National Cancer Institute (NCI)P1/2CCC (48)
pds01adc
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
pds01adc
Prostate Neoplasm
National Cancer Institute (NCI)P1/2CCC (48)
PECANS
Digestive System Disorder
Texas Tech University Health Sciences CenterP1/2CCC (48)
Peel-224
Neuroblastoma
Theodore LaetschP1/2CCC (48)
Peel-224
Rhabdomyosarcoma
Theodore LaetschP1/2CCC (48)
Pegargiminase
Diffuse Glioma, H3 G34 Mutant
Sabine Mueller, MD, PhDP1/2CCC (48)
Pegargiminase
Malignant Glioma
Sabine Mueller, MD, PhDP1/2CCC (48)
Pegenzileukin
Plasma Cell Myeloma
SanofiP1/2CCC (48)
Pegfilgrastim
Myelodysplastic Syndrome
M.D. Anderson Cancer CenterP1/2CCC (48)
Pegfilgrastim
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
M.D. Anderson Cancer CenterP1/2CCC (48)
Pegfilgrastim
Soft Tissue Sarcoma
University of California, IrvineP1/2CCC (48)
Pelareorep
Anal Carcinoma
Oncolytics BiotechP1/2CCC (48)
Pelareorep
Anal Squamous Cell Carcinoma
Oncolytics BiotechP1/2CCC (48)
Pelareorep
Exocrine Pancreatic Carcinoma
Oncolytics BiotechP1/2CCC (48)
Pelcitoclax
Non-Hodgkin Lymphoma
Ascentage Pharma Group Inc.P1/2CCC (48)
Pembrolizumab
Anaplastic Large Cell Lymphoma
AstraZenecaP1/2CCC (48)
Pembrolizumab
Central Nervous System Disorder
Reva BashoP1/2CCC (48)
Pembrolizumab
Hypopharyngeal Carcinoma
VM Oncology, LLCP1/2CCC (48)
Pembrolizumab
Laryngeal Carcinoma
VM Oncology, LLCP1/2CCC (48)
Pembrolizumab
Lip Cancer
VM Oncology, LLCP1/2CCC (48)
Pembrolizumab
Oral Cavity Cancer
VM Oncology, LLCP1/2CCC (48)
Pembrolizumab
Tonsil Carcinoma
VM Oncology, LLCP1/2CCC (48)
Showing 1626 to 1650 of 6,308 assets
PreviousPage 66 of 253Next